Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services. Further, the company provides advisory services. It serves pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, special stores, retailers, and e-commerce companies. The company was founded in 1907 and is headquartered in Espoo, Finland.
Visit company website
5 years, 5 months ago
Oriola Oyj is currently in a long term downtrend where the price is trading 1.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.
Oriola Oyj's total revenue rose by 4.4% to $466M since the same quarter in the previous year.
Its net income has increased by 356.2% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 50.0% to $41M since the same quarter in the previous year.
Based on the above factors, Oriola Oyj gets an overall score of 4/5.